Non-proliferative diabetic retinopathy
Conditions
Interventions
Experimental Group 2:Salvia miltiorrhiza combined with calcium dobesilate in the treatment of non-proliferative diabetic retinopathy
Control group:Calcium dobesilate in the treatment of non-proliferative diabetic retinopathy
Experimental Group 1:Tongluo Mingmu Combined with Calcium Dobesilate in the Treatment of Non-proliferative Diabetic Retinopathy
Sponsors
First Hospital of Northwest University
Eligibility
Sex/Gender
All
Age
30 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1.Those who meet the diagnosis criteria for type 2 diabetes and diabetic retinopathy; 2. Non-proliferative stage of diabetic retinopathy; 3. Age between 30 and 70; 4. Sign the informed consent form; 5. Women of childbearing age must have effective contraceptive measures.
Exclusion criteria
Exclusion criteria: 1. Those with uncontrolled hyperglycemia (fasting blood glucose >10mmol/L). 2. Patients with persistent hyperglycemia with HbAlc > 10%. 3. Patients after retinal photocoagulation surgery. 4. Those with other eye diseases coexisting (such as glaucoma, cataracts that significantly affect fundus examination, non-diabetic retinopathy, uveitis, retinal detachment, optic nerve diseases, and those with high myopia and fundus lesions, etc.). 5. Patients with severe primary diseases such as cardiovascular, liver, kidney and hematopoietic system diseases, serum transaminase levels greater than 1.5 times the normal value, and those with mental illness. 6. Diabetic nephropathy leads to renal failure (azotemia stage, uremia stage). 7. Pregnant women, women preparing for pregnancy or those who are breastfeeding, or those with a history of drug allergies. 8. Those who have participated in clinical trials of other drugs within the past month.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Corrected visual acuity (before the test, 4 weeks after the test, 8 weeks after the test, at the end of the test);Vision tests are scored using the international standard vision chart;Fundus changes;;Fundus fluorescein angiography results;Hemorheology (before and after the test); | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in vision;TCM syndrome points;Safety indicators; | — |
Countries
China
Contacts
Public ContactLu Yujie
First Hospital of Northwest University
Outcome results
None listed